Efficacy, safety and tolerability of recombinant factor VIII (REFACTO�) in patients with haemophilia A: interim data from a postmarketing surveillance study in Germany and Austria-Reference-Cited by-同舟云学术

Efficacy, safety and tolerability of recombinant factor VIII (REFACTO�) in patients with haemophilia A: interim data from a postmarketing surveillance study in Germany and Austria

Published:2007-03 Issue:2 Volume:13 Page:131-143
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

POLLMANN H.,EXTERNEST D.,GANSER A.,EIFRIG B.,KREUZ W.,LENK H.,PABINGER I.,SCHRAMM W.,SCHWARZ T. F.,ZIMMERMANN R.,ZAVAZAVA N.,OLDENBURG J.,KLAMROTH R.

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2516.2006.01416.x/fullpdf

Reference47 articles.

1. Hemophilia A-From Basic Science to Clinical Practice

2. Hemophilia A

3. Haemophilias A and B

4. Choice of replacement therapy for hemophilia: recombinant products only?

5. The manufacturing process for B-domain deleted recombinant factor VIII

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Non-viral and viral delivery systems for hemophilia A therapy: recent development and prospects;Annals of Hematology;2023-11-11

Safety and Efficacy of Moroctocog Alfa (AF-CC) in Chinese Patients with Hemophilia A: Results of Two Open-Label Studies

;Journal of Blood Medicine;2020-11

3. Safety of recombinant coagulation factors in treating hemophilia;Expert Opinion on Drug Safety;2019-02-01

4. Factor VIIIproducts and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: a systematic review;Journal of Thrombosis and Haemostasis;2018-05-24

5. Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden;Journal of Medical Economics;2017-12-04